Roble Belko & Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Roble Belko & Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,710	Closed	-$303K	–	349
2020 Q2	$303K	Sell	2,710 -3,055	-53%	-$301K	0.09%	64
2020 Q1	$446K	Hold	5,765	–	–	0.14%	55
2019 Q4	$548K	Buy	+5,765	New	+$499K	0.15%	53

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Roble Belko & Company's XBI Position: Q3 2020 in Review

Roble Belko & Company sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2020, closing a stake of 2,710 shares — an estimated $303K sold.

Roble Belko & Company first reported a position in XBI in Q4 2019 and held it in 3 quarters. The position peaked at $548K in Q4 2019. 554 funds tracked by Wall St. Rank hold XBI as of Q3 2020.

Roble Belko & Company reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2020 after selling out during the quarter.
Roble Belko & Company sold 2,710 State Street SPDR S&P Biotech ETF shares in Q3 2020, an estimated $303K.
Roble Belko & Company first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 3 quarters.
Roble Belko & Company's State Street SPDR S&P Biotech ETF position peaked at $548K in Q4 2019.
554 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2020.

Based on Roble Belko & Company's 13F filing for Q3 2020, filed 10 Nov 2020.